Mayo Clinic has acquired a non-exclusive license to Expression Pathology's patent for use in diagnosing systemic amyloidosis in formalin-fixed tissue. Expression Pathology said today that Mayo Clinic will use the Liquid Tissue patent in a test using mass spectrometric analysis of formalin-fixed paraffin-embedded tissue. Mayo Clinic will offer the test worldwide through its Mayo Medical Laboratories reference laboratory.

GenomeWeb, 11/18/09

Tags: Business Relations, Expression Pathology's